Dear Foregen Supporters,

Welcome back to our most recent newsletter. We have some important updates for you, and an overview of the best parts of December.

A Year in Review

  • 2019 saw the addition of two new advisory board members to our team, Elena Steiner Tartaglione, PhD and William Musa, MS. 

  • Elena graduated from Arizona State University with her PhD in Communications. Elena has extensive international experience, having worked in over 20 countries, and she continues to work with Foregen on shaping our distinct message of genital integrity and tissue engineering.


  • William graduated from Thomas Jefferson University with his MS in Biotechnology. He has experience in a variety of scientific applications, including the use of animals in a laboratory setting as well as experience working with human tissue.


  • In March we met with Flanders Investment and Trade, an agency that could help us set up research and business in Belgium to enable us to continue with the next phases of our research.


  • At the BIO-Europe conference, we met with other organizations, agencies (U.K. and Wallonia), and individuals who can facilitate the next phases of research, including tissue transportation in larger quantities in the future.


  • Foregen established discussions with several trade and investment agencies across Europe, in addition to the relationship with Flanders Investment & Trade. We concluded discussions with Berlin Partner of Economics and Technology and acquired a lead on a potential future tissue source which we’ll follow up on with the conclusion of holiday closures.


  • Foregen began the initial process for Phase III by organizing the necessary steps to undertake a full histological study of the foreskin -- something which has never be done to the extent now possible with modern technology. We have also identified a potential adult tissue supplier specifically for this phase, which would otherwise be unsuitable for Foregen’s primary experiments.


  • Our paper, which was published about a year ago on December 22nd, had a breakout entry into 2019. It scored in the top 3% of over 14 million papers ever published and tracked by Altmetric. We would like to thank all of our supporters for spreading awareness of Foregen and our publication, as well as our donors for providing funding for this project and future phases.

What's Happened Since Last Time?

  • The last of the tissue has been collected and shipped, and will be undergoing the necessary processing for proper storage in preparation for Phase II.


  • We are in discussions with an international regulatory affairs consultancy. This type of agency can create the necessary documents defining our regulatory path in different markets around the world, which is required to pursue human clinical trials, especially in the context of a for-profit transition.


  • Our legal representatives in Colombia are following up with the country’s Ministry of Health to check on the status of our request. Additional paperwork has been filed with the ministry in an attempt to expedite the process, and we’ll keep our supporters posted on new progress.


  • The project for a histological study is moving along well as a part of Phase III, and Foregen has assigned advisory board member William Musa to coordinate the bulk of the project. At this time, we have identified some potential outside partners and facilities in both the United States and Europe which have shown preliminary interest in the project.


  • Our Chief Science Officer, Eric Cunningham, is working on a related side project during the next few weeks. We’ll keep our supporters posted on the progress of his work when a new update comes along.


  • Over the past month, Foregen also had 158 new supporters sign up on our site with interest in our research.


  • For the month of December, we reached a total of $9,395 in donations, which helps us move forward with the next parts of our mission! Be sure to inform other activists, friends and family about Foregen and the science we’re pursuing to one day help provide genital integrity to men around the world. Our overall total to date is $537,831.5  Let’s keep it up.

Tell Me Something Interesting

  • According to early research from Mayo Clinic ,stem cells derived from a patient's own fat offer a step toward improving — not just stabilizing — motor and sensory function of people with spinal cord injuries. A clinical trial enrolled 10 adults to treat paralysis from traumatic spinal cord injury. After stem cell injection, the first patient demonstrated improvement in motor and sensory functions, and had no significant adverse effects, according to a case report published in Mayo Clinic Proceedings.


Thanks for reading, and stay tuned for our next newsletter. If you’d like more frequent updates, please head over to our blog, or visit one of our social media accounts – the links are in the website footer.



Tyler J. Drozd

Chief Operations Officer